Cyclooxygenase 2

• 

  Subject Areas on Research

  • 3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility. 
  • A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. 
  • A major role for the EP4 receptor in regulation of renin. 
  • A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors. 
  • A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates. 
  • ATP modulates load-inducible IL-1beta, COX 2, and MMP-3 gene expression in human tendon cells. 
  • Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in type 1 diabetes before and after disease onset. 
  • Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors. 
  • Airway inflammation and responsiveness in prostaglandin H synthase-deficient mice exposed to bacterial lipopolysaccharide. 
  • Akt expression may predict favorable prognosis in cholangiocarcinoma. 
  • An interaction between L-prostaglandin D synthase and arrestin increases PGD2 production. 
  • Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E2 and interleukin-1beta. 
  • Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase. 
  • Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia. 
  • Aspirin resistance. 
  • Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. 
  • Biological effects of desert dust in respiratory epithelial cells and a murine model. 
  • COX-2 inhibitors. 
  • COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). 
  • COX-2, MMP-9, and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. A study of 117 patients from Brazil. 
  • COX-2-derived prostacyclin modulates vascular remodeling. 
  • Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo. 
  • Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. 
  • Cell Density and Joint microRNA-133a and microRNA-696 Inhibition Enhance Differentiation and Contractile Function of Engineered Human Skeletal Muscle Tissues. 
  • Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. 
  • Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes. 
  • Chemokine CXCL1 enhances inflammatory pain and increases NMDA receptor activity and COX-2 expression in spinal cord neurons via activation of CXCR2. 
  • Cyclooxygenase 2 polymorphism (Val511Ala), nonsteroidal anti-inflammatory drug use and breast cancer in African American women. 
  • Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. 
  • Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. 
  • Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. 
  • Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. 
  • Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. 
  • Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). 
  • DIO2 modifies inflammatory responses in chondrocytes. 
  • Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. 
  • Diagnostics for aspirin resistance. 
  • Differential regulation of renin and Cox-2 expression in the renal cortex of C57Bl/6 mice. 
  • Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism. 
  • E-prostanoid-3 receptors mediate the proinflammatory actions of prostaglandin E2 in acute cutaneous inflammation. 
  • Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. 
  • Effect of size fractionation on the toxicity of amosite and Libby amphibole asbestos. 
  • Effects of sphingosine-1-phosphate and ceramide-1-phosphate on rat intestinal smooth muscle cells: implications for postoperative ileus. 
  • Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. 
  • Eicosanoids: lipid mediators of inflammation in transplantation. 
  • Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. 
  • Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways. 
  • Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer. 
  • First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. 
  • Genetic Variants in Cyclooxygenase-2 Contribute to Post-treatment Pain among Endodontic Patients. 
  • Gq-dependent signaling upregulates COX2 in glomerular podocytes. 
  • Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages. 
  • Hypoxia in the thymus: role of oxygen tension in thymocyte survival. 
  • IL-1 beta induces COX2, MMP-1, -3 and -13, ADAMTS-4, IL-1 beta and IL-6 in human tendon cells. 
  • Identification of sokotrasterol sulfate as a novel proangiogenic steroid. 
  • Impaired systemic production of prostaglandin E2 in children with cerebral malaria. 
  • In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization. 
  • Induction of cyclooxygenase-2 by mechanical stress through a nitric oxide-regulated pathway. 
  • Induction of cyclooxygenase-2 in human endometrial stromal cells by malignant endometrial epithelial cells: evidence for the involvement of extracellularly regulated kinases and CCAAT/enhancer binding proteins. 
  • Induction of cyclooxygenase-2 synthesis by ligation of the macrophage alpha(2)-macroglobulin signalling receptor. 
  • Induction of uterine prostaglandin H synthase 2 by estradiol following fetal adrenalectomy. 
  • Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. 
  • Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. 
  • Interleukin-1beta elevates cyclooxygenase-2 protein level and enzyme activity via increasing its mRNA stability in human endometrial stromal cells: an effect mediated by extracellularly regulated kinases 1 and 2. 
  • Inverse relationship of plasma prostaglandin E2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria. 
  • Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib. 
  • Lactobacillus rhamnosus GG and Bifidobacterium longum attenuate lung injury and inflammatory response in experimental sepsis. 
  • Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). 
  • Mast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam. 
  • Mathematical modeling of the Phoenix Rising pathway. 
  • Mechanical stretch is a highly selective regulator of gene expression in human bladder smooth muscle cells. 
  • Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. 
  • Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. 
  • Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E2 biosynthesis. 
  • Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2. 
  • Neonatal bacterial infection alters fever to live and simulated infections in adulthood. 
  • Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. 
  • Nonsteroidal antiinflammatory drug use among patients with GI bleeding. 
  • Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. 
  • Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS. 
  • Overexpression of human catalase inhibits proliferation and promotes apoptosis in vascular smooth muscle cells. 
  • Pathogenesis of radiation-induced capsular contracture in tissue expander and implant breast reconstruction. 
  • Persistent nuclear factor-kappa B activation in Ucp2-/- mice leads to enhanced nitric oxide and inflammatory cytokine production. 
  • Phase II trial of curcumin in patients with advanced pancreatic cancer. 
  • Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). 
  • Phenotypic abnormalities in macrophages from leptin-deficient, obese mice. 
  • Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. 
  • Podocyte-specific knockout of cyclooxygenase 2 exacerbates diabetic kidney disease. 
  • Production of prostaglandin E₂ in response to infection with modified vaccinia Ankara virus. 
  • Prostaglandin mediates premature delivery in pregnant sheep induced by estradiol at 121 days of gestational age. 
  • Pyridazinones as selective cyclooxygenase-2 inhibitors. 
  • Quantifying intrinsic specificity: a potential complement to affinity in drug screening. 
  • ROC curve estimation under test-result-dependent sampling. 
  • Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells. 
  • Reduced peripheral PGE2 biosynthesis in Plasmodium falciparum malaria occurs through hemozoin-induced suppression of blood mononuclear cell cyclooxygenase-2 gene expression via an interleukin-10-independent mechanism. 
  • Reduced spontaneous relaxation in immature guinea pig airway smooth muscle is associated with increased prostanoid release. 
  • Reduction of spinal PGE2 concentrations prevents swim stress-induced thermal hyperalgesia. 
  • Resistance to hypertension mediated by intercalated cells of the collecting duct. 
  • Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. 
  • Role of mitogen-activated protein kinase in osteoblast differentiation. 
  • Role of prostacyclin in the cardiovascular response to thromboxane A2. 
  • Selenomethionine inhibits IL-1β inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2) expression in primary human chondrocytes. 
  • Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. 
  • Skin tight: macrophage-specific COX-2 induction links salt handling in kidney and skin. 
  • Sufficient progesterone-priming prior to estradiol stimulation is required for optimal induction of the cervical prostaglandin system in pregnant sheep at 0.7 gestations. 
  • Suppression of prostaglandin E2 by malaria parasite products and antipyretics promotes overproduction of tumor necrosis factor-alpha: association with the pathogenesis of childhood malarial anemia. 
  • Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. 
  • Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. 
  • Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors. 
  • Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). 
  • The EP4 receptor for prostaglandin E2 in glomerular disease: a good receptor turned bad? 
  • The Role of Progesterone and a Novel Progesterone Receptor, Progesterone Receptor Membrane Component 1, in the Inflammatory Response of Fetal Membranes to Ureaplasma parvum Infection. 
  • The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. 
  • The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. 
  • The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs. 
  • Up-regulation of cyclooxygenase-2 expression and prostaglandin synthesis in endometrial stromal cells by malignant endometrial epithelial cells. A paracrine effect mediated by prostaglandin E2 and nuclear factor-kappa B. 
  • Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells.